Biotech Startups

NULASTIN is a beauty brand specializing in clinically formulated hair, lash, brow, and skin care products that use elastin replenishing technology. The company serves consumers seeking treatment solutions for hair loss and aesthetic concerns.

1 investor

Nula Therapeutics develops targeted small-molecule medicines that correct how the nuclear envelope regulates gene expression and cellular function. The company focuses on treating age-related diseases including metabolic dysfunction, neurodegeneration, and cancer, and on extending healthspan.

1 investor

Numares Health develops diagnostic tests that use nuclear magnetic resonance (NMR) spectroscopy and machine learning to quantify multiple biomarkers from a single serum sample for conditions related to metabolic dysfunction, including chronic kidney, liver, and cardiac diseases. Its tests serve physicians assessing disease risk and progression in the US and EU markets.

1 investor

Numb Corp develops TRPV1-targeted, botulinum-derived biologics that selectively enter sensory neurons to produce prolonged local inhibition of neurotransmission, aiming to deliver durable regional pain control. Its therapeutics are designed to be locally administered to control pain near its source while avoiding the systemic exposure associated with conventional pain medicines, including opioids.

1 investor

Numenos builds patient-centric biological world models that learn from individual patient data across all diseases to discover the causal mechanisms underlying human biology. The platform applies machine learning to biology with the aim of enabling individualized treatments.

1 investor

Numiera is a biotech company developing new cancer therapeutics based on the study of tumor biology and cancer cell metabolism. It uses a preclinical platform to test novel therapies and aims to move basic research findings into oncology clinical trials.

1 investor

Nuo Therapeutics is a commercial-stage medical device company developing biodynamic therapies for wound care. Its flagship product, Aurix, is a hematogel that uses a patient's own platelets and plasma to promote healing.

1 investor

Developing 'Epi-drugs' that modulate epigenetic targets for cancer and other diseases.

1 investor

NuPulseCV develops the Voyage device, a cardiac support technology aimed at patients with heart failure who are treated at both major institutions and community hospitals. The company is guided by a scientific advisory board of clinically active cardiologists and cardiac surgeons.

1 investor

Nurture Genomics applies newborn genomic sequencing to identify genetic risk markers in children, drawing on research from the BabySeq Project. It serves pediatric healthcare by translating genomics research into clinical insights for children's health.

1 investor

ADM is expanding its natural food colour production capabilities at its Kentucky facility to serve food and beverage manufacturers transitioning away from synthetic colorants due to regulatory pressure and consumer preference shifts. The expansion will increase capacity for liquid and dry-blended color solutions derived from natural sources.

1 investor

NutriLeads employs in-house experts with backgrounds in food technology, microbiology, nutrition, and health across academic and industry sectors. The company appears to operate in the food and nutrition space with a focus on ingredient or food technology solutions.

1 investor

Nutt Bio is developing a single-injection sterilant for male pigs that achieves the same outcomes as surgical castration, used to prevent boar taint. The product is aimed at the swine industry, developed in collaboration with farm vets, researchers, and farm workers.

1 investor

Nuvectis is a biopharmaceutical company developing oral small molecule therapies for cancer, including NXP900, an SRC Family Kinase inhibitor, and NXP800, a GCN2 activator being evaluated in solid tumors such as ovarian cancer and cholangiocarcinoma. Its drug candidates are in early-stage clinical trials for patients with advanced solid tumors.

1 investor

Nuvig Therapeutics is a biotech company developing immune-modulating therapies for autoimmune and chronic inflammatory diseases, using an endogenous regulatory mechanism intended to treat inflammation without compromising broader immune function. It targets patients with autoimmune conditions.

1 investor

NuVision develops ocular biotherapies rooted in translational research from the University of Nottingham, aiming to provide patients with immediate access to innovative eye surface repair and regeneration treatments. The company operates across the UK, Middle East, Nordics, and central Europe.

1 investor

NuvOx Therapeutics is a clinical-stage pharmaceutical company developing NanO₂, an oxygen therapeutic drug intended to improve oxygen flow from lungs to blood and to tissue in order to reverse tissue hypoxia. Its clinical programs target indications including glioblastoma (as a radio sensitizer), stroke, and respiratory distress.

1 investor

Nxtcure Labs operates an AI-based, full-stack contract research organization (CRO) that helps move therapeutics from discovery through to market, alongside a mobile platform that guides cancer patients through treatment. It serves pharmaceutical and biotech drug developers as well as patients in the healthcare and drug discovery sector.

1 investor

CyteType is a cell type annotation tool for single-cell RNA-seq data that provides evidence trails for annotations, Cell Ontology standardization, and disease context handling. It supports multiple deployment options including on-premise and cloud hosting, with deterministic reproducibility for regulatory and QC applications.

1 investor

Nykode Therapeutics is a biotechnology company; this investor relations page provides shareholder information, financial reports, and corporate governance details but does not describe the company's specific products or therapeutic focus.

1 investor

NyquistAI provides an AI-powered intelligence platform that aggregates clinical and regulatory documentation into searchable information and insights for life science companies. It operates in the health technology and life sciences data space.

1 investor

Dimericon Therapeutics is a biotech company developing crosslinked helix dimers ("Dimericons") as therapeutics and as templates for small-molecule development, targeting hard-to-drug intracellular protein-protein interactions. Its lead program focuses on hematological malignancies, with a seed round supporting preclinical work toward an IND-ready clinical candidate.

1 investor

Obalon Therapeutics was a Carlsbad, California medical device company that developed an FDA-approved swallowable, gas-filled intragastric balloon system for non-surgical weight loss in obese adults.

1 investor

Oban Biopharma develops allosteric GPCR-targeted therapeutics for metabolic and CNS/neuropsychiatric diseases, using computational structural and chemotype analysis combined with AI-based druggability filters to identify drug candidates. Its pipeline focuses on allosteric modulators of clinically validated GPCR targets intended to offer efficacy with fewer side effects than traditional orthosteric drugs.

1 investor